Valbiotis share breaks through 0.55 € support and slides into oversold territory
The La Rochelle-based laboratory continues its decline during the session, following a particularly heavy first day. Semi-annual results and the abandonment of several commercial ambitions continue to dominate the file, in a Paris market oriented upward.
A broken support and an RSI below 30 after yesterday's fall
The Valbiotis share falls 4.92% to 0.52 € while the CAC 40 gains 0.62%. The security broke through its 0.55 € support during the session, which it is unable to reclaim. The nearest resistance is at 0.81 €.
The RSI at 29.61 drops below the 30 mark, following a decline of 18.05% over the week, and the price remains well below its moving averages: the gap reaches 23.24% with the 20-day MA and 41.35% with the 200-day MA. The decline occurs after Tuesday's session, which had sent the security to a historic low. Over one year, the share is now down 33.15%.
An abandonment of 2026, 2027 and 2030 targets that weighs on expectations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The H1 2026 accounts, published on October 12, show a net loss reduced to 3.4 M€ and cash of 11.7 M€ following the June capital increase. The company however abandoned its ambition of 3 M€ in revenue for 2026, as well as its 2027 and 2030 targets, with third quarter commercial momentum remaining below expectations. Two research firms reacted on October 13 by lowering their price targets while maintaining their buy ratings, according to analysts' consensus: TP Icap Midcap lowered it from 1.80 € to 1.30 € and Portzamparc from 1.90 € to 1.40 €. These new targets remain significantly higher than the current share price.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0,8 millions d'euros
Quarterly revenue: 0,8 millions d'euros
Net income: -3,4 millions d'euros
Guidance from the release
« Valbiotis renonce par prudence à son ambition de chiffre d'affaires à 3 M€ sur l'ensemble de l'exercice 2026 » et retire ses ambitions 2027 et 2030
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
